Initiator Pharma A/S (STO:INIT)

Market Cap	338.07M
Revenue (ttm)	n/a
Net Income (ttm)	-19.87M
Shares Out	56.16M
EPS (ttm)	-0.36
PE Ratio	n/a
Forward PE	4.14
Dividend	n/a
Ex-Dividend Date	n/a

Volume	49,245
Average Volume	31,950
Open	6.24
Previous Close	6.28
Day's Range	5.76 - 6.34
52-Week Range	5.22 - 11.75
Beta	0.35
RSI	42.95
Earnings Date	Apr 28, 2025

About Initiator Pharma

Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes IPED2015, a drug candidate which is in clinical phase 2a for the treatment of organic erectile dysfunction; IP2018, a monoamine reuptake inhibitor completed Phase IIa for the treatment of psychogenic erectile dysfunction primarily targeting the serotonin followed by the dopamine system; and IPTN2021, a Phase 1 clinical drug program targeting an orphan drug indic...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 2
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: INIT

Financial Performance

Financial numbers in DKK